Smad3 and Smad7 Genes Expression in TGF-β Signaling Pathway in Patients with Acute Lymphoblastic Leukemia
International Journal of Medical Laboratory · 20.05.2026
DOI: 10.18502/ijml.v12i2.21571 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Medical Laboratory, online erschienen am 20.05.2026. Verfasst von Sedigheh Ekraminasab und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy characterized by the clonal expansion of immature lymphoid blasts in the bone marrow, affecting both children and adults. The transforming growth factor-β/ Smad signaling pathway, a critical tumor-suppressor pathway, is frequently dysregulated in various cancers. This study aimed to investigate the expression levels of Smad3 and Smad7 in ALL patients to assess potential dysregulation. Materials and Methods: We analyzed bone marrow and peripheral blood samples from 52 newly diagnosed ALL patients (including 20 pediatrics and 32 adults) and 15 healthy controls. Samples were assessed for morphology, immunocytochemistry, immunophenotyping, and molecular markers. Reverse transcription quantitative real-time polymerase chain reaction was used to evaluate Smad3 and Smad7 expression levels.
Results
Compared to the control group, ALL leukemia patients exhibited a statistically significant downregulation of Smad3 and upregulation of Smad7. The oncogenic role of Smad7 was more prominent in specific subtypes, with its expression being significantly higher in pediatric ALL compared to adult ALL, and in B-ALL compared to T-ALL.
Conclusions
Our findings suggest that decreased Smad3 (a key receptor-regulated Smad) and elevated Smad7 (an inhibitory Smad) may contribute to Transforming growth factor-β pathway resistance, potentially playing a role in ALL pathogenesis. This study highlights the involvement of Smad dysregulation in patients with ALL, offering insights into molecular mechanisms and potential therapeutic targets. Further research is warranted to validate these findings and explore clinical applications.
Zitieren
APA
Ekraminasab, S., Farsani, M. A., Hamidpour, M., Nezhad, H. A., & Azizzadeh, A. (2026). Smad3 and Smad7 Genes Expression in TGF-β Signaling Pathway in Patients with Acute Lymphoblastic Leukemia. International Journal of Medical Laboratory. https://doi.org/10.18502/ijml.v12i2.21571
Vancouver
Ekraminasab S, Farsani MA, Hamidpour M, Nezhad HA, Azizzadeh A. Smad3 and Smad7 Genes Expression in TGF-β Signaling Pathway in Patients with Acute Lymphoblastic Leukemia. International Journal of Medical Laboratory. 2026. doi:10.18502/ijml.v12i2.21571
BibTeX
@article{Ekraminasab2026,
author = {Ekraminasab, Sedigheh and Farsani, Mehdi Allahbakhshian and Hamidpour, Mohsen and Nezhad, Hamideh Aghaee and Azizzadeh, Amirmohammad},
title = {Smad3 and Smad7 Genes Expression in TGF-β Signaling Pathway in Patients with Acute Lymphoblastic Leukemia},
journal = {International Journal of Medical Laboratory},
year = {2026},
doi = {10.18502/ijml.v12i2.21571}
}
EUVIMED